Ascendis Pharma Bone Diseases A/S: palopegteriparatide

January 31, 2023. We reserve further comment on the proposed labeling until the application is otherwise adequate.

Any additional specific details of these required postmarketing studies, including a timetable and annual reporting requirements, will be described more fully in the approval letter for this application, if it is approved.